Emcure Pharmaceuticals Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Emcure Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 22 May 2025.

Powered by Capital Market - Live News

The company received the Establishment Inspection Report (EIR) from the USFDA following an inspection conducted between 19 February 2025 and 25 February 2025. According to an exchange filing dated 26 February 2025, the inspection concluded with the issuance of two observations in Form 483.

Pune-based Emcure Pharmaceuticals is a leading Indian pharma company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products.

The company?s consolidated net profit surged 35.5% to Rs 153.72 crore in Q3 FY25 as against Rs 113.45 crore posted in Q3 FY24. Revenue from operations jumped 17.7% YoY to Rs 1,962.63 crore in the quarter ended 31 December 2024.

The scrip shed 0.89% to Rs 1,084.95 on the BSE.

Powered by Capital Market - Live News

The APA has also been inked with the subsidiaries of Manx, viz. Manx Pharma and Manx Generics.

Tillomed Laboratories is a leading European pharmaceutical company focused on developing, licensing, and marketing high-quality generic medicines. Headquartered in Luton, UK, Tillomed operates across multiple European markets, ensuring access to cost-effective healthcare solutions.

Under the APA, Tillomed will acquire Manx?s product portfolio inclusive of relevant dossiers, marketing authorisations, intellectual property and the relevant stocks for around ?19.7 million (including ?4.7 million for inventory).

Of the total consideration, ?6.2 million will be upfront and rest as milestone payments over the next 18 months.

Commenting on the development, Ajit Srimal, CEO, Tillomed said: ?Through the acquisition of Manx?s established and high-quality products portfolio, we reinforce our commitment to delivering accessible healthcare solutions.

The acquired assets will help diversify our portfolio and strengthen our market presence.?

Pune-based Emcure Pharmaceuticals is a leading Indian pharma company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products.

The company?s consolidated net profit surged 35.5% to Rs 153.72 crore in Q3 FY25 as against Rs 113.45 crore posted in Q3 FY24. Revenue from operations jumped 17.7% YoY to Rs 1,962.63 crore in the quarter ended 31 December 2024.

The scrip tumbled 4.90% to currently trade at Rs 982.60 on the BSE.

Powered by Capital Market - Live News

The company received the Establishment Inspection Report (EIR) from the USFDA following an inspection conducted between 19 February 2025 and 25 February 2025. According to an exchange filing dated 26 February 2025, the inspection concluded with the issuance of two observations in Form 483.

Pune-based Emcure Pharmaceuticals is a leading Indian pharma company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products.

The company?s consolidated net profit surged 35.5% to Rs 153.72 crore in Q3 FY25 as against Rs 113.45 crore posted in Q3 FY24. Revenue from operations jumped 17.7% YoY to Rs 1,962.63 crore in the quarter ended 31 December 2024.

The scrip shed 0.89% to Rs 1,084.95 on the BSE.

Powered by Capital Market - Live News

The APA has also been inked with the subsidiaries of Manx, viz. Manx Pharma and Manx Generics.

Tillomed Laboratories is a leading European pharmaceutical company focused on developing, licensing, and marketing high-quality generic medicines. Headquartered in Luton, UK, Tillomed operates across multiple European markets, ensuring access to cost-effective healthcare solutions.

Under the APA, Tillomed will acquire Manx?s product portfolio inclusive of relevant dossiers, marketing authorisations, intellectual property and the relevant stocks for around ?19.7 million (including ?4.7 million for inventory).

Of the total consideration, ?6.2 million will be upfront and rest as milestone payments over the next 18 months.

Commenting on the development, Ajit Srimal, CEO, Tillomed said: ?Through the acquisition of Manx?s established and high-quality products portfolio, we reinforce our commitment to delivering accessible healthcare solutions.

The acquired assets will help diversify our portfolio and strengthen our market presence.?

Pune-based Emcure Pharmaceuticals is a leading Indian pharma company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products.

The company?s consolidated net profit surged 35.5% to Rs 153.72 crore in Q3 FY25 as against Rs 113.45 crore posted in Q3 FY24. Revenue from operations jumped 17.7% YoY to Rs 1,962.63 crore in the quarter ended 31 December 2024.

The scrip tumbled 4.90% to currently trade at Rs 982.60 on the BSE.

Powered by Capital Market - Live News

Tillomed Laboratories, a subsidiary of Emcure Pharmaceuticals, has entered into an Asset Purchase Agreement (APA) with UK based Manx Healthcare and its subsidiaries, Manx Pharma and Manx Generics (collectively Manx).

Under the APA, Tillomed will acquire Manx's product portfolio inclusive of relevant Dossiers, Marketing Authorisations, Intellectual Property (collectively Intellectual Properties) and the relevant stocks for around ? 19.7 mn (including ? 4.7mn for inventory) of which ? 6.2 mn will be upfront and rest as milestone payments over the next 18 months.

The deal marks a strategic milestone for Tillomed and will strengthen the company's product offerings, expand its market reach, and enhance its ability to meet the evolving needs of patients.

Commenting on the development, Ajit Srimal, CEO Tillomed said, ?Through the acquisition of Manx's established and high-quality products portfolio, we reinforce our commitment to delivering accessible healthcare solutions. The acquired assets will help diversify our portfolio and strengthen our market presence.?

Powered by Capital Market - Live News

Emcure Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 22 May 2025.

Powered by Capital Market - Live News

The company received the Establishment Inspection Report (EIR) from the USFDA following an inspection conducted between 19 February 2025 and 25 February 2025. According to an exchange filing dated 26 February 2025, the inspection concluded with the issuance of two observations in Form 483.

Pune-based Emcure Pharmaceuticals is a leading Indian pharma company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products.

The company?s consolidated net profit surged 35.5% to Rs 153.72 crore in Q3 FY25 as against Rs 113.45 crore posted in Q3 FY24. Revenue from operations jumped 17.7% YoY to Rs 1,962.63 crore in the quarter ended 31 December 2024.

The scrip shed 0.89% to Rs 1,084.95 on the BSE.

Powered by Capital Market - Live News

The APA has also been inked with the subsidiaries of Manx, viz. Manx Pharma and Manx Generics.

Tillomed Laboratories is a leading European pharmaceutical company focused on developing, licensing, and marketing high-quality generic medicines. Headquartered in Luton, UK, Tillomed operates across multiple European markets, ensuring access to cost-effective healthcare solutions.

Under the APA, Tillomed will acquire Manx?s product portfolio inclusive of relevant dossiers, marketing authorisations, intellectual property and the relevant stocks for around ?19.7 million (including ?4.7 million for inventory).

Of the total consideration, ?6.2 million will be upfront and rest as milestone payments over the next 18 months.

Commenting on the development, Ajit Srimal, CEO, Tillomed said: ?Through the acquisition of Manx?s established and high-quality products portfolio, we reinforce our commitment to delivering accessible healthcare solutions.

The acquired assets will help diversify our portfolio and strengthen our market presence.?

Pune-based Emcure Pharmaceuticals is a leading Indian pharma company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products.

The company?s consolidated net profit surged 35.5% to Rs 153.72 crore in Q3 FY25 as against Rs 113.45 crore posted in Q3 FY24. Revenue from operations jumped 17.7% YoY to Rs 1,962.63 crore in the quarter ended 31 December 2024.

The scrip tumbled 4.90% to currently trade at Rs 982.60 on the BSE.

Powered by Capital Market - Live News

The company received the Establishment Inspection Report (EIR) from the USFDA following an inspection conducted between 19 February 2025 and 25 February 2025. According to an exchange filing dated 26 February 2025, the inspection concluded with the issuance of two observations in Form 483.

Pune-based Emcure Pharmaceuticals is a leading Indian pharma company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products.

The company?s consolidated net profit surged 35.5% to Rs 153.72 crore in Q3 FY25 as against Rs 113.45 crore posted in Q3 FY24. Revenue from operations jumped 17.7% YoY to Rs 1,962.63 crore in the quarter ended 31 December 2024.

The scrip shed 0.89% to Rs 1,084.95 on the BSE.

Powered by Capital Market - Live News

The APA has also been inked with the subsidiaries of Manx, viz. Manx Pharma and Manx Generics.

Tillomed Laboratories is a leading European pharmaceutical company focused on developing, licensing, and marketing high-quality generic medicines. Headquartered in Luton, UK, Tillomed operates across multiple European markets, ensuring access to cost-effective healthcare solutions.

Under the APA, Tillomed will acquire Manx?s product portfolio inclusive of relevant dossiers, marketing authorisations, intellectual property and the relevant stocks for around ?19.7 million (including ?4.7 million for inventory).

Of the total consideration, ?6.2 million will be upfront and rest as milestone payments over the next 18 months.

Commenting on the development, Ajit Srimal, CEO, Tillomed said: ?Through the acquisition of Manx?s established and high-quality products portfolio, we reinforce our commitment to delivering accessible healthcare solutions.

The acquired assets will help diversify our portfolio and strengthen our market presence.?

Pune-based Emcure Pharmaceuticals is a leading Indian pharma company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products.

The company?s consolidated net profit surged 35.5% to Rs 153.72 crore in Q3 FY25 as against Rs 113.45 crore posted in Q3 FY24. Revenue from operations jumped 17.7% YoY to Rs 1,962.63 crore in the quarter ended 31 December 2024.

The scrip tumbled 4.90% to currently trade at Rs 982.60 on the BSE.

Powered by Capital Market - Live News

Tillomed Laboratories, a subsidiary of Emcure Pharmaceuticals, has entered into an Asset Purchase Agreement (APA) with UK based Manx Healthcare and its subsidiaries, Manx Pharma and Manx Generics (collectively Manx).

Under the APA, Tillomed will acquire Manx's product portfolio inclusive of relevant Dossiers, Marketing Authorisations, Intellectual Property (collectively Intellectual Properties) and the relevant stocks for around ? 19.7 mn (including ? 4.7mn for inventory) of which ? 6.2 mn will be upfront and rest as milestone payments over the next 18 months.

The deal marks a strategic milestone for Tillomed and will strengthen the company's product offerings, expand its market reach, and enhance its ability to meet the evolving needs of patients.

Commenting on the development, Ajit Srimal, CEO Tillomed said, ?Through the acquisition of Manx's established and high-quality products portfolio, we reinforce our commitment to delivering accessible healthcare solutions. The acquired assets will help diversify our portfolio and strengthen our market presence.?

Powered by Capital Market - Live News